MCID: UVL004
MIFTS: 60

Uveal Melanoma

Categories: Genetic diseases, Eye diseases, Rare diseases, Cancer diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Uveal Melanoma

MalaCards integrated aliases for Uveal Melanoma:

Name: Uveal Melanoma 12 56 52 42 14 69
Malignant Melanoma of Choroid 69
Malignant Melanoma of Iris 69
Choroidal Melanoma 56
Melanoma of Uvea 12
Melanoma, Uveal 24
Iris Melanoma 56

Characteristics:

Orphanet epidemiological data:

56
uveal melanoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult,elderly;

HPO:

32
uveal melanoma:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 56  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:6039
MeSH 42 C536494
NCIt 47 C7712
Orphanet 56 ORPHA39044
MESH via Orphanet 43 C536494
UMLS via Orphanet 70 C0220633 C0346373 C0346388
ICD10 via Orphanet 34 C69.3
UMLS 69 C0220633

Summaries for Uveal Melanoma

Disease Ontology : 12 A uveal cancer that has material basis in uvea pigment cells.

MalaCards based summary : Uveal Melanoma, also known as malignant melanoma of choroid, is related to posterior uveal melanoma and malignant iris melanoma, and has symptoms including visual loss, choroidal melanoma and retinal detachment. An important gene associated with Uveal Melanoma is GNAQ (G Protein Subunit Alpha Q), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Ranibizumab and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and retina, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and homeostasis/metabolism

Wikipedia : 72 Uveal melanoma is a cancer (melanoma) of the eye involving the iris, ciliary body, or choroid... more...

Related Diseases for Uveal Melanoma

Diseases in the Uveal Melanoma family:

Melanoma, Uveal 2 Melanoma, Uveal 1
Posterior Uveal Melanoma

Diseases related to Uveal Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 118)
id Related Disease Score Top Affiliating Genes
1 posterior uveal melanoma 12.2
2 malignant iris melanoma 12.1
3 malignant choroid melanoma 12.1
4 necrotic uveal melanoma 12.1
5 melanoma, uveal 2 12.0
6 melanoma, uveal 1 12.0
7 mixed cell uveal melanoma 12.0
8 ocular melanoma 11.3
9 tumor predisposition syndrome 11.2
10 classic phenylketonuria 11.1 GNA11 GNAQ
11 melanoma 11.1
12 mirror polydactyly-vertebral segmentation-limbs defects syndrome 11.1 BAP1 BRAF
13 raf1-related noonan syndrome 11.0 BRAF NRAS
14 secondary pulmonary hemosiderosis 11.0 CDK4 CDKN2A MET
15 epidural neoplasm 11.0 CDK4 CDKN2A VEGFC
16 tietz albinism-deafness syndrome 11.0 MITF TYR
17 ovarian serous adenofibroma 11.0 GNA11 GNAQ NRAS
18 vulval paget's disease 11.0 CDKN2A NRAS TYR
19 cystic lymphangioma 11.0 CDK4 CDKN2A MMP2
20 post-surgical hypoinsulinemia 10.9 CDK4 CDKN2A GNA11 GNAQ
21 large cell carcinoma with rhabdoid phenotype 10.9 BAP1 CDKN2A MET
22 familial idiopathic steroid-resistant nephrotic syndrome with minimal changes 10.9 BRAF CDKN2A S100B
23 small cell sarcoma 10.9 CDK4 CDKN2A GNA11 GNAQ
24 malignant breast melanoma 10.9 BRAF S100B TYR
25 split hand split foot nystagmus 10.9 BRAF CDKN2A
26 diencephalic astrocytomas 10.9 BRAF CDK4 CDKN2A TIMP3
27 fibrous meningioma 10.9 CDKN2A GNA11 GNAQ NRAS
28 olfactory neural tumor 10.9 CDKN2A GNA11 GNAQ NRAS
29 differentiating neuroblastoma 10.9 IGF1R MET S100B
30 commad syndrome 10.9 MITF TYR
31 oligomeganephronic renal hypoplasia 10.9 IGF1R MMP2 S100B
32 tracheal disease 10.9 CDKN2A MMP2 VEGFC
33 trachea carcinoma in situ 10.9 MET MMP2 VEGFC
34 hodgkin's lymphoma, mixed cellularity 10.9 CDKN2A MMP2 VEGFC
35 pharynx cancer 10.9 BAP1 CDK4 CDKN2A GNA11 GNAQ
36 fasciolopsiasis 10.9 CDKN2A MC1R MMP2
37 endocervical type cervical adenomyoma 10.9 MITF PMEL
38 hanhart syndrome 10.9 PMEL TYR
39 juvenile nasopharyngeal angiofibroma 10.9 BRAF S100B
40 mantle cell lymphoma 10.9 CDK4 CDKN2A MET MMP2
41 melanocytic nevus syndrome, congenital, somatic 10.9 MC1R NRAS TYR
42 periventricular nodular heterotopia 6 10.9 CDKN2A MET S100B
43 chorea, hereditary benign 10.8 BRAF MET VEGFC
44 kidney hypertrophy 10.8 CDKN2A MITF S100B
45 non-distal trisomy 10q 10.8 BRAF MET NRAS
46 autism susceptibility 16 10.8 MITF PMEL TYR
47 facial hemiatrophy 10.8 BAP1 CDKN2A MC1R NRAS
48 hartnup disorder 10.8 BRAF CDK4 CDKN2A MET MMP2
49 gallbladder cancer 10.8 CDKN2A MET MMP2
50 basosquamous carcinoma 10.8 BAP1 BRAF

Graphical network of the top 20 diseases related to Uveal Melanoma:



Diseases related to Uveal Melanoma

Symptoms & Phenotypes for Uveal Melanoma

Human phenotypes related to Uveal Melanoma:

56 32 (show all 18)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 visual loss 56 32 hallmark (90%) Very frequent (99-80%) HP:0000572
2 choroidal melanoma 56 32 hallmark (90%) Very frequent (99-80%) HP:0012054
3 retinal detachment 56 32 frequent (33%) Frequent (79-30%) HP:0000541
4 iris melanoma 56 32 frequent (33%) Frequent (79-30%) HP:0011524
5 ciliary body melanoma 56 32 frequent (33%) Frequent (79-30%) HP:0012055
6 abnormality of refraction 56 32 occasional (7.5%) Occasional (29-5%) HP:0000539
7 vitreous hemorrhage 56 32 occasional (7.5%) Occasional (29-5%) HP:0007902
8 increased intraocular pressure 56 32 occasional (7.5%) Occasional (29-5%) HP:0007906
9 inferior lens subluxation 56 32 occasional (7.5%) Occasional (29-5%) HP:0008494
10 zonular cataract 56 32 occasional (7.5%) Occasional (29-5%) HP:0010920
11 mydriasis 56 32 occasional (7.5%) Occasional (29-5%) HP:0011499
12 metamorphopsia 56 32 occasional (7.5%) Occasional (29-5%) HP:0012508
13 photopsia 56 32 occasional (7.5%) Occasional (29-5%) HP:0030786
14 abnormal visual accommodation 56 32 occasional (7.5%) Occasional (29-5%) HP:0030800
15 inflammatory abnormality of the eye 56 32 very rare (1%) Very rare (<4-1%) HP:0100533
16 ocular pain 56 32 very rare (1%) Very rare (<4-1%) HP:0200026
17 abnormality of the fundus 56 Very frequent (99-80%)
18 intraocular melanoma 32 HP:0007716

GenomeRNAi Phenotypes related to Uveal Melanoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.91 CDH5 IGF1R
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.91 IGF1R
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.91 TIMP3
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-175 9.91 CDH5
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.91 CDH5
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 9.91 CDH5
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.91 GNA11
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.91 TIMP3
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.91 IGF1R
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 9.91 CDH5
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.91 GNA11
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 9.91 CDH5 GNA11 IGF1R TIMP3
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.91 TIMP3
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-98 9.91 GNA11
15 Decreased cell migration GR00055-A-1 9.55 MET VEGFC BRAF CDK4 IGF1R
16 Decreased substrate adherent cell growth GR00193-A-1 9.32 IGF1R MET
17 Decreased substrate adherent cell growth GR00193-A-2 9.32 CDK4
18 Decreased substrate adherent cell growth GR00193-A-3 9.32 BRAF CDK4 MET
19 Decreased substrate adherent cell growth GR00193-A-4 9.32 BRAF CDK4 IGF1R MET

MGI Mouse Phenotypes related to Uveal Melanoma:

44 (show all 24)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.53 BAP1 BRAF CDH5 CDK4 CDKN2A CYSLTR2
2 cardiovascular system MP:0005385 10.49 GNA11 GNAQ IGF1R MET MMP2 NRAS
3 immune system MP:0005387 10.49 TIMP3 TYR VEGFC BAP1 BRAF CDH5
4 growth/size/body region MP:0005378 10.45 BAP1 BRAF CDH5 CDK4 CDKN2A GNA11
5 behavior/neurological MP:0005386 10.43 S100B TIMP3 TYR BRAF CDK4 CDKN2A
6 hematopoietic system MP:0005397 10.43 MC1R MITF MMP2 NRAS PMEL SF3B1
7 integument MP:0010771 10.43 S100B TIMP3 TYR BAP1 BRAF CDH5
8 endocrine/exocrine gland MP:0005379 10.4 BAP1 BRAF CDH5 CDK4 CDKN2A GNA11
9 cellular MP:0005384 10.38 BAP1 BRAF CDH5 CDK4 CDKN2A IGF1R
10 mortality/aging MP:0010768 10.38 BAP1 BRAF CDH5 CDK4 CDKN2A GNA11
11 craniofacial MP:0005382 10.34 BRAF CDH5 GNA11 GNAQ IGF1R MC1R
12 embryo MP:0005380 10.29 BAP1 BRAF CDH5 CDK4 CDKN2A IGF1R
13 muscle MP:0005369 10.16 CDKN2A GNA11 GNAQ IGF1R MET MMP2
14 liver/biliary system MP:0005370 10.15 BRAF CDH5 CDK4 CDKN2A GNA11 IGF1R
15 neoplasm MP:0002006 10.13 NRAS TYR BAP1 BRAF CDK4 CDKN2A
16 hearing/vestibular/ear MP:0005377 10.11 BRAF GNA11 GNAQ IGF1R MC1R MITF
17 limbs/digits/tail MP:0005371 10.11 NRAS TYR GNA11 GNAQ IGF1R MC1R
18 normal MP:0002873 10.11 BRAF CDH5 CDK4 GNA11 GNAQ MET
19 pigmentation MP:0001186 10.06 BRAF CDK4 CDKN2A GNA11 GNAQ MC1R
20 no phenotypic analysis MP:0003012 10.01 BAP1 CDKN2A MC1R MET MITF NRAS
21 respiratory system MP:0005388 9.85 BAP1 BRAF CDKN2A CYSLTR2 GNA11 GNAQ
22 renal/urinary system MP:0005367 9.8 GNAQ MET TIMP3 TYR BRAF CDK4
23 skeleton MP:0005390 9.61 BRAF CDKN2A GNA11 GNAQ IGF1R MITF
24 vision/eye MP:0005391 9.36 BRAF CDH5 CDK4 CDKN2A MET MITF

Drugs & Therapeutics for Uveal Melanoma

Drugs for Uveal Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3 347396-82-1 459903
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 124-94-7 31307
3 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
4 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
5 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3
6 glucocorticoids Phase 4,Phase 2,Phase 3
7 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
8 Hormones Phase 4,Phase 2,Phase 3,Phase 1
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1
10 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
11 triamcinolone acetonide Phase 4,Phase 2,Phase 3
12 Triamcinolone diacetate Phase 4,Phase 2,Phase 3
13 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3
14
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
15
Melphalan Approved Phase 3,Phase 2 148-82-3 4053 460612
16
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
17
Imidazole Experimental Phase 3,Phase 2 288-32-4 795
18
Fotemustine Experimental Phase 3
19 Alkylating Agents Phase 3,Phase 2,Phase 1
20 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
21 Vaccines Phase 3,Phase 2,Phase 1
22 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1
23 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Early Phase 1
24 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1
25
Sorafenib Approved, Investigational Phase 2,Phase 1 284461-73-0 216239 406563
26
Bevacizumab Approved, Investigational Phase 2 216974-75-3
27
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
28
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
29
Sunitinib Approved, Investigational Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
30
Tamoxifen Approved Phase 2 10540-29-1 2733526
31
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
32
Everolimus Approved Phase 2 159351-69-6 6442177
33
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
34
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
35
Somatostatin Approved Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
36
Ethiodized oil Approved Phase 2 8008-53-5
37
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
38
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
39
Peginterferon alfa-2b Approved Phase 2 99210-65-8, 215647-85-1
40
Aluminum hydroxide Approved Phase 2 21645-51-2
41
Aluminum sulfate Approved Phase 2 10043-01-3
42
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
43
Lomustine Approved Phase 2 13010-47-4 3950
44
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
45
Vorinostat Approved, Investigational Phase 2,Early Phase 1 149647-78-9 5311
46
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
47
Pancrelipase Approved Phase 2 53608-75-6
48
Trametinib Approved Phase 2,Phase 1 871700-17-3 11707110
49
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
50
nivolumab Approved Phase 1, Phase 2 946414-94-4

Interventional clinical trials:

(show top 50) (show all 135)

id Name Status NCT ID Phase Drugs
1 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
2 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
3 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
4 Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) Completed NCT01974752 Phase 3 75mg selumetinib;placebo;Dacarbazine
5 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
6 Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma Recruiting NCT01983748 Phase 3
7 The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases Recruiting NCT01785316 Phase 3
8 Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma Recruiting NCT02678572 Phase 3 Dacarbazine;Ipilimumab;Pembrolizumab
9 Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma Active, not recruiting NCT02843386 Phase 3 Adjuvant chemotherapy by Fotemustin
10 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma Terminated NCT00110123 Phase 3 fotemustine;isolated perfusion
11 Vaccine Therapy in Treating Patients With Melanoma of the Eye Terminated NCT00036816 Phase 3
12 A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma Unknown status NCT01377025 Phase 2 Placebo;Sorafenib;Sorafenib
13 Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye Unknown status NCT01217398 Phase 2 temozolomide
14 Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Unknown status NCT00489944 Phase 2 cisplatin;sunitinib malate;tamoxifen citrate
15 Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy Unknown status NCT02586727 Phase 2 aflibercept
16 Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma Completed NCT01034787 Phase 2 CP-675,206
17 Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma Completed NCT00506142 Phase 2 Marqibo® (vincristine sulfate liposomes injection)
18 RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma Completed NCT01252251 Phase 2 RAD001 (Everolimus) and Pasireotide (SOM230) LAR
19 Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination Completed NCT02517736 Phase 2 Sorafenib at a dose of 800 mg / day
20 Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Completed NCT00661622 Phase 2 GM-CSF
21 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery Completed NCT00738361 Phase 2 nab-paclitaxel
22 Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01143402 Phase 2 Dacarbazine;Selumetinib;Temozolomide
23 Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Completed NCT01413191 Phase 2
24 Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye Completed NCT00329641 Phase 2 carboplatin;paclitaxel;sorafenib tosylate
25 Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00003339 Phase 2
26 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma Completed NCT00084656 Phase 2
27 Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00027742 Phase 2 temozolomide
28 Vaccine Therapy in Treating Patients With Metastatic Melanoma Completed NCT00334776 Phase 2
29 PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma Completed NCT00238329 Phase 2 thalidomide
30 Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye Completed NCT00020475 Phase 2 gp100 antigen;interleukin-2;MART-1 antigen;Montanide ISA-51
31 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Completed NCT00089206 Phase 2
32 Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma Completed NCT00089219 Phase 1, Phase 2
33 Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma Completed NCT00005815 Phase 1, Phase 2 temozolomide;thalidomide
34 Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Completed NCT00003802 Phase 2 pyrazoloacridine
35 Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma Completed NCT00032045 Phase 2
36 Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma Completed NCT00031733 Phase 2 alum adjuvant
37 Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma Completed NCT00058279 Phase 1, Phase 2
38 Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma Completed NCT00072345 Phase 2 lomustine;temozolomide;thalidomide
39 Melanoma Vaccine With Peptides and Leuprolide Completed NCT00254397 Phase 2 Leuprolide
40 Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Completed NCT00121225 Phase 2 vorinostat
41 Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma Completed NCT00085189 Phase 2 Montanide ISA 51 VG;agatolimod sodium
42 VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00450255 Phase 2
43 AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma Completed NCT00243061 Phase 2 cediranib maleate
44 Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma Completed NCT00288041 Phase 2 carboplatin;paclitaxel;bortezomib
45 Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma Completed NCT00085306 Phase 2
46 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
47 Taxoprexin® Treatment for Advanced Eye Melanoma Completed NCT00244816 Phase 2 Taxoprexin
48 THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease Completed NCT01355120 Phase 2 Ipilimumab
49 Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases Recruiting NCT02913417 Phase 1, Phase 2 ipilimumab;nivolumab
50 Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis Recruiting NCT02936388 Phase 2

Search NIH Clinical Center for Uveal Melanoma

Cochrane evidence based reviews: uveal melanoma

Genetic Tests for Uveal Melanoma

Genetic tests related to Uveal Melanoma:

id Genetic test Affiliating Genes
1 Melanoma, Uveal 24 GNA11 GNAQ

Anatomical Context for Uveal Melanoma

MalaCards organs/tissues related to Uveal Melanoma:

39
Eye, Liver, Retina, Testes, Endothelial, Bone, Skin

Publications for Uveal Melanoma

Articles related to Uveal Melanoma:

(show top 50) (show all 598)
id Title Authors Year
1
Predictors of radio-induced visual impairment after radiosurgery for uveal melanoma. ( 28903963 )
2017
2
Germline BAP1 alterations in familial uveal melanoma. ( 27718540 )
2017
3
The Long Non-Coding RNA RHPN1-AS1 Promotes Uveal Melanoma Progression. ( 28124977 )
2017
4
Grb2-associated binder 2 expression and its roles in uveal melanoma invasion. ( 28791340 )
2017
5
PRiMeUM: A Model for Predicting Risk of Metastasis in Uveal Melanoma. ( 28828481 )
2017
6
miR-367 promotes uveal melanoma cell proliferation and migration by regulating PTEN. ( 28829890 )
2017
7
Surgery vs. radiotherapy in patients with uveal melanoma : Analysis of the SEER database using propensity score matching and weighting. ( 28879443 )
2017
8
Growth of Uveal Melanoma following Intravitreal Bevacizumab. ( 28868282 )
2017
9
Prognostic value of apoptosis inducing factor in uveal melanoma. ( 28043154 )
2017
10
Uveal Melanoma with Histopathologic Intratumoral Heterogeneity Associated with Gene Expression Profile Discordance. ( 28868288 )
2017
11
Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands. ( 27911126 )
2017
12
A GWAS in uveal melanoma identifies risk polymorphisms in the CLPTM1L locus. ( 28781888 )
2017
13
Lentiviral-mediated overexpression of KCTD12 inhibits the proliferation of human uveal melanoma OCM-1 cells. ( 28000887 )
2017
14
Immunotherapy of Uveal Melanoma: Vaccination Against Cancer. ( 27987156 )
2017
15
Isolated uveal melanoma metastases to the heart: take a look at chest X-ray! ( 28950292 )
2017
16
PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. ( 28448663 )
2017
17
Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma. ( 28069617 )
2017
18
Prognostic Implications of the Largest Basal Tumor Diameter vs the TNM Staging System in Association With the Gene Expression Profile for Uveal Melanoma-Reply. ( 28056125 )
2017
19
Prognostic Implications of the Largest Basal Tumor Diameter vs the TNM Staging System in Association With the Gene Expression Profile for Uveal Melanoma. ( 28056132 )
2017
20
Gene expression profiling in uveal melanoma: technical reliability and correlation of molecular class with pathologic characteristics. ( 28778171 )
2017
21
Comparison of primary and secondary enucleation for uveal melanoma. ( 28812919 )
2017
22
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. ( 28810145 )
2017
23
INTRAVITREAL DEXAMETHASONE (OZURDEX) IMPLANT FOR RADIATION MACULOPATHY SECONDARY TO STEREOTACTIC RADIOTHERAPY FOR POSTERIOR UVEAL MELANOMA. ( 28489707 )
2017
24
Melanogenesis in uveal melanoma cells: Effect of argan oil. ( 28849034 )
2017
25
Local Failure After Episcleral Brachytherapy for Posterior Uveal Melanoma: Patterns, Risk Factors, and Management. ( 28756956 )
2017
26
Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. ( 28881222 )
2017
27
Multiple Pigmented Conjunctival Lesions following Intravitreal Injections in a Patient with Uveal Melanoma. ( 28868281 )
2017
28
Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls. ( 28935400 )
2017
29
The first description of the complete natural history of uveal melanoma by two Scottish surgeons, Allan Burns and James Wardrop. ( 28834323 )
2017
30
RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. ( 28486107 )
2017
31
Genetic and Epigenetic Insights into Uveal Melanoma. ( 28902406 )
2017
32
Uveal Melanoma Regression after Brachytherapy: Relationship with Chromosome 3 Monosomy Status. ( 28868276 )
2017
33
Local Failure After Episcleral Brachytherapy for Posterior Uveal Melanoma: Patterns, Risk Factors, and Management. ( 28163118 )
2017
34
Uveal Melanoma Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis. ( 28823399 )
2017
35
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. ( 27921276 )
2016
36
Update on Ophthalmic Oncology 2014: Retinoblastoma and Uveal Melanoma. ( 27632029 )
2016
37
Oncogenic role of microRNAa8920a in human uveal melanoma. ( 27356499 )
2016
38
Uveal Melanoma Mimicking Advanced Coats' Disease in a Young Patient. ( 27239453 )
2016
39
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. ( 27089179 )
2016
40
Proton therapy for the management of uveal melanoma and other ocular tumors. ( 27558251 )
2016
41
Clinical application of genetic testing for posterior uveal melanoma. ( 27847622 )
2016
42
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. ( 27507190 )
2016
43
Metastatic Disease in Polyploid Uveal Melanoma Patients Is Associated With BAP1 Mutations. ( 27116551 )
2016
44
Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation. ( 28042502 )
2016
45
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. ( 27476772 )
2016
46
Analysis of caveolin-1 and phosphoinositol-3 kinase expression in primary uveal melanomas. ( 26590370 )
2016
47
Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma. ( 27453764 )
2016
48
Clinicopathological Characteristics and Prognosis for Survival after Enucleation of Uveal Melanoma in Chinese Patients: Long-term Follow-up. ( 27911584 )
2016
49
Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases. ( 26923342 )
2016
50
Uveal Melanoma Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis). ( 28018010 )
2016

Variations for Uveal Melanoma

Copy number variations for Uveal Melanoma from CNVD:

7 (show all 33)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13320 1 1 124300000 Copy number Uveal melanoma
2 15978 1 120700000 121100000 Nomal NOTCH2 Uveal melanoma
3 21742 1 16100000 20300000 Nomal NBL1 Uveal melanoma
4 32197 1 34400000 46500000 Nomal MYCBP Uveal melanoma
5 32198 1 34400000 46500000 Nomal PTAFR Uveal melanoma
6 33591 1 46500000 51300000 Nomal MUTYH Uveal melanoma
7 35197 1 60900000 84700000 Nomal RPE65 Uveal melanoma
8 37517 1 9200000 12600000 Nomal MFN2 Uveal melanoma
9 166068 3 1 199501827 Copy number Uveal melanoma
10 168175 3 127700000 131500000 Loss Rho Uveal melanoma
11 170048 3 150400000 153500000 Loss MME Uveal melanoma
12 172555 3 18400000 104400000 Loss CPO Uveal melanoma
13 173444 3 193800000 199501827 Loss OPA1 Uveal melanoma
14 174743 3 32100000 43600000 Loss CTNNB1 Uveal melanoma
15 175394 3 39300000 43600000 Loss MLH1 Uveal melanoma
16 175735 3 43600000 51400000 Loss SEMA3B Uveal melanoma
17 177570 3 58500000 63700000 Loss FHIT Uveal melanoma
18 178910 3 81800000 83700000 Loss ROBO1 Uveal melanoma
19 179180 3 8700000 11500000 Loss FANCD2 Uveal melanoma
20 179181 3 8700000 11500000 Loss VHL Uveal melanoma
21 203641 6 1 170899992 Copy number Uveal melanoma
22 205639 6 130400000 131300000 Nomal CTGF Uveal melanoma
23 207759 6 160900000 164400000 Nomal IGF2R Uveal melanoma
24 209014 6 2300000 4100000 Nomal Uveal melanoma
25 209045 6 23500000 26100000 Nomal DCDC2 Uveal melanoma
26 210240 6 29900000 45200000 Nomal RUNX2 Uveal melanoma
27 212309 6 36800000 40600000 Nomal CDKN1A Uveal melanoma
28 232746 8 119200000 122500000 Gain MYC Uveal melanoma
29 233772 8 127300000 140000000 Gain DDEF1 Uveal melanoma
30 238089 8 29700000 38500000 Nomal NRG1 Uveal melanoma
31 240056 8 45200000 146274826 Copy number Uveal melanoma
32 240078 19 67920024 67921999 Gain GDF-15 Uveal melanoma
33 240624 8 52800000 55600000 Gain RP1 Uveal melanoma

Expression for Uveal Melanoma

Search GEO for disease gene expression data for Uveal Melanoma.

Pathways for Uveal Melanoma

Pathways related to Uveal Melanoma according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 BRAF CDH5 CDK4 CDKN2A GNA11 IGF1R
2
Show member pathways
13.63 BRAF CDK4 CDKN2A GNA11 IGF1R MET
3
Show member pathways
13.18 BRAF CDH5 IGF1R MET NRAS TIMP3
4
Show member pathways
12.95 GNA11 IGF1R MET NRAS TIMP3 VEGFC
5
Show member pathways
12.94 BRAF GNA11 IGF1R MET NRAS TIMP3
6
Show member pathways
12.76 BRAF GNA11 GNAQ MET NRAS
7
Show member pathways
12.59 BRAF GNAQ IGF1R MET NRAS VEGFC
8
Show member pathways
12.45 BRAF CDK4 CDKN2A IGF1R MET MITF
9
Show member pathways
12.3 BRAF GNA11 GNAQ NRAS
10
Show member pathways
12.21 GNAQ MC1R MITF NRAS TYR
11
Show member pathways
12.15 BRAF CDK4 IGF1R MET NRAS
12 12.11 BRAF IGF1R MET MMP2 NRAS TIMP3
13 11.96 BRAF CDK4 CDKN2A GNA11 GNAQ IGF1R
14 11.81 BRAF CDK4 CDKN2A IGF1R NRAS
15 11.79 CDK4 MMP2 NRAS VEGFC
16 11.76 BRAF GNA11 GNAQ
17 11.67 CDH5 MMP2 TIMP3 VEGFC
18 11.56 GNA11 GNAQ MMP2
19 11.54 BRAF CDK4 GNAQ IGF1R
20 11.53 IGF1R MMP2 TIMP3
21 11.49 BRAF GNA11 GNAQ IGF1R NRAS TIMP3
22 11.42 BRAF CDK4 CDKN2A MMP2 NRAS
23 11.23 GNA11 GNAQ MET
24 11.13 BRAF GNA11 GNAQ IGF1R NRAS

GO Terms for Uveal Melanoma

Biological processes related to Uveal Melanoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.85 BRAF CDK4 CYSLTR2 GNA11 GNAQ IGF1R
2 G-protein coupled acetylcholine receptor signaling pathway GO:0007213 9.46 GNA11 GNAQ
3 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.43 GNA11 GNAQ
4 melanin biosynthetic process GO:0042438 9.4 PMEL TYR
5 phototransduction, visible light GO:0007603 9.37 GNA11 GNAQ
6 blood vessel maturation GO:0001955 9.32 CDH5 MMP2
7 entrainment of circadian clock GO:0009649 9.26 GNA11 GNAQ
8 regulation of melanocyte differentiation GO:0045634 8.96 GNA11 GNAQ
9 developmental pigmentation GO:0048066 8.8 GNA11 GNAQ PMEL

Molecular functions related to Uveal Melanoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 BAP1 BRAF CDH5 CDK4 CDKN2A CYSLTR2
2 type 2A serotonin receptor binding GO:0031826 8.62 GNA11 GNAQ

Sources for Uveal Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....